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Background: Mooren’s ulcer is a severe ulcerative inflammation of the cornea. The exact pathogenesis remains
unclear. Therefore many therapies of Mooren’s ulcer are recommended in literature. To shed more light on the
ongoing question of optimal treatment of severe progressive Mooren’s ulcer, we here report on a retrospective
case series of patients treated with systemic immunosuppressive therapy and additional amniotic membrane
transplantation.
Methods: Medical records from seven patients (eleven eyes), 4 male and 3 female, with severe progressive
Mooren’s ulcer were analysed retrospectively. The mean follow up was 88.4 ± 80.8 months (range 12–232 month).
A HLA-typing was performed in all patients. A systemic immunosuppressive therapy was administered in all
patients. The amniotic membrane was transplanted after the base of the ulcer was resected.
Results: Multiple amniotic membrane transplantations were necessary in six patients. The visual outcome of all
patients was poor. No patient achieved a visual acuity better than 20/630 Snellen chart. Five patients were positive
for HLA-DQ2 and four patients were positive for HLA-DR17(3).
Conclusions: The aggressive and highly inflammatory form of Mooren’s ulcer is difficult to treat and the
progression of the disease is hard to influence positively even under systemic immunosuppressive therapy.
Therefore, the main intention of therapy is to achieve a stable epithelialized corneal surface without the risk of
perforation. Amniotic membrane transplantation is not able to cure severe forms of Mooren’s ulcer. However it
supports the immunosuppressive therapy in acute situations as in critical corneal thinning.
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Mooren’s ulcer is a severe ulcerative, uni- or bilateral
inflammation of the cornea. Typically the inflammation
starts in the peripheral cornea and the ulcer enlarges
centrally and circumferentially – commonly associated
with severe ocular pain. In late stages of the disease the
destruction of the peripheral corneal stroma results in a
conjunctivalized descemet membrane and in some cases
corneal perforations occur. The progression and out-
come of Mooren’s ulcer differ between patients though
the clinical appearance is similar. The exact pathogenesis* Correspondence: maurice.schallenberg@uk-essen.de
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distribution, and reproduction in any mediumremains unclear even though the disease was first de-
scribed by Bowman more than 150 years ago [1]. It is
consensus that the Mooren’s ulcer is an autoimmune
disease that targets the cornea without other systemic
disease association. Support for this idea came from
Gottsch and colleagues who found antibodies against
Calgranulin C in the serum of patients with Mooren’s
ulcer [2,3]. Calgranulin C is uniquely expressed in cor-
nea stromal tissue. Epidemiological studies from India
identified a history of ocular trauma, previous cataract
surgery, bacterial and helminth infection as risk factors
to develop Mooren’s ulcer [4].
Furthermore the disease occurs in populations living
abroad and second generation migrants. Therefore the
question of genetic predisposition arises. The highlyentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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portant role in immune response. An association to
several autoimmune diseases such as rheumatoid arthritis,
Graves’disease, and multiple sclerosis has been described
[5]. Taylor and coworkers identified an association of HLA-
DR17(3) and HLA-DQ2 to Mooren’s ulceration [6].
Various therapies of Mooren’s ulcer are recommended
in literature. The excision of the conjunctiva around the
ulceration combined with local or systemic steroids or
coagulation of the base of the ulceration showed no
long term benefit [7,8]. Authors from a large Chinese
study of 550 patients who were treated with lamellar
keratoplasty after topical resection of the ulceration,
concluded that an adjuvant medication of topical ciclos-
porin A 1% eye drops improves outcome [9]. They recom-
mended topical ciclosporin A as therapeutic approach
to modulate immune response. The stepladder of im-
munosuppressive agents used in Mooren’s ulcer include
prednisolone, methotrexate, azathioprine, cyclosporine,
cyclophosphamide, and infliximab [9-12].
Recent studies suggest amniotic membrane transplant-
ation (AMT) as a therapeutic approach in Mooren’s ulcer.
The idea of amniotic membrane transplantation as a thera-
peutic option in Mooren’s ulcer came from the positive
results shown by AMT of corneal ulceration due to other
reasons. However, results reported in the literature with
this procedure vary widely.
Recently, a retrospective study of 18 eyes reported a
stabilization of the visual acuity and rapid healing of
the epithelial defect after single AMT in most cases
[13]. In contrast, results of AMT combined with con-
junctival autografting or lamellar keratoplasty are less
convincing [14,15].
The growing evidence that Mooren’s ulceration has an
autoimmune genesis suggests an immunosuppressive
therapy in Mooren’s ulceration. In addition to systemic ster-
oid therapy, ciclosporin A or cyclophosphamide is recom-
mended in cases with severe progression or relapse [16,17].
To shed more light on the ongoing question of optimal
treatment of severe progressive Mooren’s ulcer, we here
report a retrospective case series of patients treated with
systemic immunosuppressive therapy and additional AMT.
Methods
Medical records from patients with severe progressive
Mooren’s ulcer were analysed retrospectively. They
were treated between October 2002 and April 2012 at
the University Eye Hospital Essen, Essen, Germany.
The study was approved by the local ethics committee
(Ethics Committee of the University Duisburg-Essen Nr.
13-5501-BO) and adhered to the tenets of the Declaration
of Helsinki and local law.
Mooren’s ulcer was diagnosed if an idiopathic painful
peripheral corneal ulceration with typical clinical featuresand absence of scleral inflammation was observed. Infection
was excluded by clinical and microbiological investigations.
Other diagnoses causing peripheral corneal ulcerations
(e.g. rheumatoid arthritis, Wegner’s granulomatosis, other
collagen vascular diseases, inflammatory bowel diseases,
rosacea, Terrien’s degeneration, or pellucid degeneration)
were excluded by interdisciplinary clinical assessments
and laboratory investigations. A HLA-typing was per-
formed in all patients.
The systemic immunosuppressive therapy was adminis-
tered in close collaboration with the clinic for hematology
and clinic for nephrology of the University Hospital Essen,
Essen, Germany to monitor the potentially serious side
effects and the drug levels.
In cases of severe corneal thinning and highly inflamma-
tory ulceration an AMT was performed. The amniotic
membrane was obtained from the Cornea Bank Essen. The
method of amniotic membrane preparation has been previ-
ous described by Kim and Tseng [18]. The surgical proced-
ure was performed under peribulbar anaesthesia. The base
of the ulcer was resected and an amniotic membrane graft
(basement membrane oriented up) of similar size and shape
was laid into the defect and sutured with 10–0 nylon
sutures. In some cases the procedure was combined
with a conjunctival resection and / or amniotic membrane
patch which was sutured with 8–0 vicryl sutures to the
peribulbar conjunctiva.
The clinical findings and therapeutic response of AMT in
addition to local and systemic immunosuppressive therapy
were determined.
Results
Eleven eyes of seven patients, 4 male and 3 female, were
enrolled in this retrospective interventional cases series.
The mean age at the first presentation in our clinic was
62.8 ± 15.7 years (range 37–81 years). The mean follow up
was 88.4 ± 80.8 months (range 12 – 232 month). Details
of the patients’ characteristics and clinical features
are summarized in Table 1. One patient had a severe
aggressive form of Mooren’s ulcer on both eyes. In all
other cases, one eye was affected by severe aggressive
Mooren’s ulcer with large deep ulcerations, the other
eye was not affected in three cases, and only mild
affected in the other three cases, respectively. Five patients
were treated with intravenous cyclophosphamide as
pulsetherapy and 2 patients with ciclosporin A orally
as continuous therapy under drug monitoring. In addition,
the patients were treated with ciclosporin A 0.05% eye
drops three times daily as local immunosuppressive
therapy. The supportive local therapy consisted of prednis-
olone acetate 1% three times daily, and sodium hyaluronate
0.1% and dexpanthenol, each instilled six times a day.
Furthermore autologous serum 20% eye drops were
applied six times a day.
Table 1 Clinical features of patients with Mooren’s ulceration
Case No. Eye Age HLA DQ2 / DR17(3) Depth of ulcer
1 both 81 +/+ 2/3
2 OD 68 +/− 2/3
3 OD 68 −/− 2/3
4 OD 37 −/+ 2/3
5 both 70 +/+ 2/3
6 both 45 +/+ Perforation
7 both 71 +/− 2/3
Figure 1 Representative images of the processes in some
patients. a) - e) Right eye of case No. 5: a) corneal ulcer at the first
visit; b) progression of the ulceration; c) + d) follow up after AMT;
e) opacified epithelialized cornea at the last visit. f) – j) Left eye of case
No. 1: f) peripheral corneal ulcer at the first visit; g) progression of the
ulceration; h) + i) follow up after AMT; j) opacified epithelilized cornea
at the last visit. k) – m) Right eye of case No.7: k) corneal ulcer at the
first visit; l) progression of the ulceration; m) stabilized cloudy cornea
with peripheral pannus after AMT and with immunosuppressive
therapy. n) – o) Right eye of case No. 2: n) 360° peripheral ulcer at the
first visit; o) stabilized cornea with peripheral opacified scar under
immunosuppressive therapy after AMT.
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patients were positive for HLA-DR17(3).
In 6 patients multiple AMTs were necessary because
of relapsing ulceration or persistent epithelial defects. A
stabilization of the disease was achieved after one amni-
otic membrane grafting in only one patient. Representa-
tive images of the processes are presented in Figure 1.
The visual outcome of all patients was poor. No pa-
tient achieved a visual acuity better than 20/630 Snellen
chart in the affected eye with severe aggressive Mooren’s
ulceration. Details of surgical procedure, follow up, im-
munosuppressive therapy and visual outcome are sum-
marized in Table 2.
Discussion
Mooren’s ulceration is a rare ulcerative inflammation of
the cornea with quite a variable clinical progression and
outcome for the patients. The diagnosis of Mooren’s
ulceration is difficult because other diseases causing a
peripheral corneal ulceration have to be excluded in
advance. Therefore, randomized prospective therapy studies
are difficult to conduct and to date, even a recent Cochrane
review in 2011 identified no randomized controlled trials
for treatment of Mooren’s ulcer [19].
Reviewing the literature, only case reports or retro-
spective cases series are published recommending thera-
peutic approaches based on theoretical considerations
[3,9,14,16,17]. The definition of success seems to differ
in the published literature. While some studies defined
“healing” as success others used the “visual acuity” as
primary end point [19].
The natural course of Mooren’s ulceration is very dif-
ferent. In addition to the aggressive ulcerative forms,
chronically inflammatory forms and spontaneous re-
missions are described. These facts make it difficult to
evaluate and to compare the different recommended
therapeutic approaches. Furthermore, the mean follow
up after treatment is usually not longer than two years
and in some reports no mean follow up is stated [9].
We report on seven Mooren’s ulcer patients in a long-
term follow up. The mean follow up in our interventional
case series is 88.4 months ± 80.8. To our knowledge thisis the longest follow up ever published on patients with
Mooren’s ulcer.
Wood and Kaufman classified Mooren’s ulcer into two
main forms according to the age of onset, clinical char-
acteristics, and the prognosis [20]. Type 1 is the benign
form, generally monolateral with mild to moderate
symptoms. This type was believed to affect mostly adults
(over 35 years) and responds well to medical treatment
and surgery. In contrast, type 2 is the malignant form that
occurs with relatively more pain and generally responses
poorly to any treatment. This type affects mostly younger
patients (younger than 35 years) and a bilateralcondition
in up to 75% of the cases that were reported in black
patients. The classification of Watson divided the disease
into three types based on the clinical appearance: (1) unilat-
eral Mooren’s ulcer, (2) bilateral aggressive Mooren’s ulcer,
and (3) bilateral indolent Mooren’s ulcer [10]. With regard
to bilaterality, perforation, age of onset, and recurrence rate
Table 2 Follow up and therapy modalities of patients with Mooren’s ulceration
Case No. Follow up
time (month)
Numbers of AM- transplantation/
Surgical procedures






1 112 OD: 2x + KPL Cyclophosphamide (i.v.; ineffective)
FK-506
Cyclosporin A AT 0.5% OD: < 20/4000 OD: <20/4000 2 month after AMT and effective
immunosuppressive therapy
OS: 3x OS: 20/4000 OS: 20/4000
2 75 OD: 1x Cyclosporin A (orally) Cyclosporin A AT 0.5% OD: 20/2000 OD: 20/4000 3 month after AMT and effective
immunosuppressive therapy
3 14 OD: 4x Cylclophosphamide (i.v.) Cyclosporin A AT 0.5% OD: 20/80 OD: 20/2000 1 month after AMT and effective
immunosuppressive therapy
4 12 OD: 1x Cyclophosphamide (i.v.) Cyclosporin A AT 0.5% OD: 20/32 OD: 20/80 1 month after AMT and effective
immunosuppressive therapy
5 144 OD: 7x + conjunctival resection Cyclophosphamide (i.v.; ineffective)
Cyclosporin A (orally; ineffective)
Tacrolimus
Cyclosporin A AT 0.5% OD: 20/32 OD: <20/4000 3 month after AMT and effective
immunosuppressive therapy
OS: 20/20 OS: 20/32
6 232 OD: 4x + KPL enucleation Cyclophosphamide (i.v.) Cyclosporin A AT 0.5% OD: 20/25 OD: - 3 month after KPL and effective
immunosuppressive therapy
OS: 20/25 OS: 20/40
7 30 OD: 5x + conjunctival resection Cyclophosphamide (i.v.)
Azathioprine
Cyclosporin A AT 0.5% OD: 20/320 OD: 20/800 3 month after AMT and effective
immunosuppressive therapy
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and Kaufman. We report on cases of aggressive Mooren’s
ulcer in elderly patients (mean age 62.8 years ± 15.6). These
findings are supported by Lewallen and Courtright review-
ing the literature on 287 cases of Mooren’s ulcer who found
a bilateral disease in 43% of older patients [21]. Chen and
coworkers published a consecutive cases series of 550 pa-
tients obtained similar results, concluding that the bilateral
disease is the malignant type of Mooren’s ulcer [9]. Their
findings are in contrast to the result of our case series,
in which malignant aggressive processes were observed
in unilateral Mooren’s ulcer.
HLA-DQ2 and/or HLA-DR17(3) have been suggested
to have a positive correlation to Mooren’s ulcer. All of
our patients tested positive for HLA-DQ2 or HLA-DR17
(3). We believe that the expression of HLA-DQ2 and/or
HLA-DR17(3) may serve as prognostic factor in Mooren’s
ulceration, and may help to distinguish the severe ag-
gressive form from the mild benign form of the disease.
Further studies with larger patient cohorts are required
to investigate this suggestion.
The growing evidence of Mooren’s ulceration as an
autoimmune disease has led to the recommendation of
systemic immunosuppressive therapy in severe progressive,
highly inflammative Mooren’s ulcer [22]. Cyclophospamide
and ciclosporin A are the most commonly used agents.
Cyclophosphamide may be affective by suppressing B
lymphocytes, which produce autoantibodies and promote
an immune complex reaction [23]. In contrast, ciclosporin
A may work by suppression of the T helper cell and
stimulation of the T suppressor cell and cytotoxic T cells
[24]. Both therapies are able to halt the progression in many
patients with Mooren’s ulcer [16,24,25]. Despite the use of
the systemic immunosuppressive therapy in all patients,
additional AMT was necessary because of a persistent
peripheral corneal ulceration or a progressive corneal
thinning. These findings are in accordance with the results
of Mondino and Spelsberg who report on a progression
of Mooren’s ulceration under systemic immunosuppressive
therapy in some cases [25,26].
It is well known that AMT is able to improve the
corneal epithelialisation and to support the remission
of inflammation, neovascularisation, and corneal scars
in several corneal diseases. The mechanism of action of
AMT is to induce the apoptosis in inflammatory cells, the
release of protease inhibitors, and suppression of fibroblast
proliferation [27]. The most important growth factors that
promote wound healing, which have been isolated from the
AM, are epidermal growth factor and keratocyte growth
factor [28,29]. In addition, the AM produces basic fibro-
blast, hepatocyte and transforming growth factor (TGF).
These growth factors together can stimulate epithelialisa-
tion, modulate proliferation, and induce differentiation of
stromal fibroblasts [30].The inhibition of TGF-β signal transduction in corneal
fibroblasts explains AM’s anti-scarring effect [31]. In
the initial phase after AMT, a significant reduction in
inflammation is typical. The AM reduces expression of
various growth factors and pro-inflammatory cytokines
(e.g. interleukin 1a, IL −2, IL-8, interferon γ, tumor necrosis
factor-β, basic fibroblast growth factor and platelet derived
growth factor) [32]. Furthermore, the AM attracts and
adheres to inflammatory cells infiltrating the ocular
surface. In addition, the AM contains various forms of
protease inhibitors [33]. This may explain some of its
antiinflammatory properties. The reported immuno-
modulatory effect underlines the suggestion that AMT
has a positive effect in healing Mooren’s ulcer [34].
Recently, a retrospective study of 18 eyes reported a
stabilization of the visual acuity and rapid healing of the
epithelial defect after single AMT in most cases [13]. Ngan
and Chau reported in a rapid epithelialisation and a good
visual outcome especially in patients with limited corneal
ulceration. In patients with 360° ulceration, as was seen
in most of our cases, the time of epithelialisation was
up to one month and the visual outcome was poor. An-
other limitation of this study is the short follow up time
(1.5 to 20 month). In addition, the authors did not ensure
their diagnosis by assessing HLA-DQ2 and HLA-DR17(3).
The reported results of AMTcombined with conjunctival
autografting or lamellar keratoplasty are less convincing
[14,15]. The authors claimed a positive effect of AMT in
their studies but there are several limitations. Zhou and col-
leagues combined AMT with lamellar keratoplasty for pa-
tients with recurrent Mooren’s ulcer. They found a delayed
recurrence in their cases but they did not differentiate the
effect of lamellar keratoplasty from the AMT. In addition,
they reported a short follow up time (12 to 29 month).
Chen et al. reported on one case of initial successfully
sealed corneoscleral perforation, a relapse after 2 months
with infiltration along the conjuncival graft. After removing
the conjuntival graft and a second AMT the leason was
stable over 1 year. One case has a very limited value in a
disease in which the natural course is very different and
spontaneous remissions are described.
In contrast to those studies we report on cases of aggres-
sive Mooren’s ulcer with large coneal ulcers in which AMT
was not able to stabilize the processes of the disease. In
most of our cases (6 of 7) we could identify HLA-DQ2
or HLA-DR17(3) which seems to be highly associated to
Mooren’s ulcer and may be a prognostic factor. These
findings emphasize our diagnosis of Mooren’s ulcer.
The anti-inflammatory potential of amniotic membrane
may be useful in Mooren’s ulcer in some cases to support
the systemic immunosuppressive therapy. The fact that 5
patients needed multiple AMT showed clearly that amniotic
membrane is not able to stop the immunological process or
even cure Mooren’s ulcer in aggressive processes.
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In conclusion, the aggressive highly inflammatory form
of Mooren’s ulcer is difficult to treat and so far there is
no optimal therapy for Mooren’s ulcer. The progression
of the disease is hard to influence positively even under
systemic immunosuppressive therapy and intensive local
medication. Therefore, the main intention of therapy is
to achieve a stable epithelialized corneal surface without
the risk of perforation than to maintain the visual acuity.
AMT is not able to cure severe forms of Mooren’s ulcer
because the disease is based on an immunological process.
However it supports the immunosuppressive therapy in
acute situations like critical corneal thinning or persistent
epithelial defects.
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